WNT1 and cancer: Most importantly, our current studies provide a specific framework for cancer immunotherapy through Wnt1 inhibition, acting to unleash DC immunity, coupled to cDC expansion with Flt3L and/or selective targeting of tumor antigens on cDCs via aDEC205.